We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Breast Screening for Women over 70 Does Not Result in Sharp Drop in Advanced Disease

By MedImaging International staff writers
Posted on 22 Sep 2014
Print article
Breast screening for women over age 70 does not prompt a sharp fall in advanced disease. Instead, it may just lead to overdiagnosis and overtreatment, suggests new findings by Dutch researchers.

The researchers led by a team based at Leiden University Medical Center (The Netherlands) are presenting their data at the Preventing Overdiagnosis Conference, held September 15–17, 2014, in Oxford (UK), where experts worldwide will discuss how to handle the threat to health and the waste of money caused by unnecessary care. The conference is hosted by the Center for Evidence-Based Medicine at the University of Oxford (UK) in partnership with the British Medical Journal (BMJ) "Too Much Medicine campaign."

The upper age limit for the national breast cancer screening program was extended to women aged 69 to 75 in 1998 in the Netherlands, and national guidelines now recommend screening women up to the age of 75. This is in spite of no strong evidence showing that screening much older women is effective, according to the researchers, due to the scarcity of this age group in any of the clinical trials on which the policy is founded. However, breast cancer is the most common cancer and biggest cause of death from cancer in women worldwide. Furthermore, as populations age, the percentage of older women who are diagnosed with the disease is set to increase in the developed world.

The researchers therefore set out to find whether the national breast screening program in the Netherlands has made a significant impact in the numbers of late stage cancers among 70–75 year old—a hallmark of success. They monitored all new cases of invasive and non-invasive (in situ) breast cancer, diagnosed in this age group from 1995 up to 2011, using data from the Netherlands Cancer Registry. They separated cases into the period before (1995-7), after (2003-11), and in-between (1998-2002) the introduction of the national screening program, which came to almost 25,500 in all. Furthermore, they included 13,000 women aged 76–80, to take account of any changes in breast cancer incidence among older women ineligible for national screening.

Data analysis showed that new cases of early stage breast cancer among 70–75 year olds rose sharply after national screening was introduced, from 248.7 to 362.9 per 100,000 women. However, while there was a substantial decrease in the numbers of new cases of advanced breast cancer, the absolute decrease was small; dropping from 58.6 before, to 51.8 instances per 100,000 women after, the national screening program was introduced.

Among 76–80 year olds, new cases of early stage disease fell slightly, but the numbers of new cases of advance breast cancer did not change. The researchers calculated, based on the figures, that for every advanced stage cancer detected by screening among 70–75 year olds, around 20 “extra” and therefore “overdiagnosed” early stage tumors are identified, which the researchers described as a “considerable proportion.”

Overdiagnosis and overtreatment are important, the researchers emphasized, because they can undermine quality of life, and because older individuals are more susceptible to the side effects of breast cancer treatment. Moreover, they come with a potentially huge cost in return for little obvious health benefit, the investigators pointed out. “Instead of using mass screening, the decision to participate in the screening program should be personalized, based on remaining life expectancy, breast cancer risk, functional status and patients’ preferences,” the authors concluded.

The study’s findings were published September 16, 2014, in the British Medical Journal (BMJ).

Related Links:

Leiden University Medical Center


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Advanced Cardiac MRI Analysis Software
3Di Cardiac MR
New
Thyroid Shield
Standard Thyroid Shield
New
Brachytherapy Planning System
Oncentra Brachy

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.